CollPlant Biotechnologies (CLGN) Debt Ratio (2017 - 2020)

CollPlant Biotechnologies' (CLGN) quarterly Debt Ratio came in at 0.0 in Q2 2020, down 50.9% on a QoQ basis from 0.0 in Q4 2019.

CollPlant Biotechnologies (CLGN) Debt Ratio (2017 - 2020) Analysis & Trends

CollPlant Biotechnologies (CLGN) has 4 years of Debt Ratio data on file, last reported at 0.0 in Q2 2020.

Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q2 2020, while the trailing twelve-month figure through Jun 2020 was 0.0 (changed N/A YoY) and the FY2019 annual result came in at 0.0, changed N/A from the prior year.
Debt Ratio slipped to 0.0 in Q2 2020, from 0.0 in the prior quarter.
In the past five years, Debt Ratio ranged from a high of 0.45 in Q4 2017 to a low of 0.0 in Q2 2020.
A 4-year average of 0.12 and a median of 0.01 in 2018 frame the typical range for Debt Ratio.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.05
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.26
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.47
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.03
10	CollPlant Biotechnologies	4.13 Mn	4.13 Mn	-243,000.00	-

Download Data